The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Biomarin Pharmaceutical Inc

Nasdaq: BMRN
Last

(U.S.) $85.09

Today's change0.00 0.00%
Updated May 3 4:00 PM EDT. Delayed by at least 15 minutes.
 

Biomarin Pharmaceutical Inc

Nasdaq: BMRN
Last

(U.S.) $85.09

Today's change0.00 0.00%
Updated May 3 4:00 PM EDT. Delayed by at least 15 minutes.

Biomarin Pharmaceutical Inc closed at (U.S.)$85.09.

Over the last five days, shares have lost 4.08% and are down 18.78% for the last year to date. This security has underperformed the S&P 500 by 24.47% during the last year.

Key company metrics

  • Open(U.S.) $0.00
  • Previous close(U.S.) $85.09
  • High--
  • Low--
  • Bid / Ask(U.S.) $83.12 / (U.S.) $87.00
  • YTD % change-18.78%
  • Volume0
  • Average volume (10-day)1,781,595
  • Average volume (1-month)1,637,336
  • Average volume (3-month)1,782,121
  • 52-week range(U.S.) $62.12 to (U.S.) $151.75
  • Beta0.96
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$1.08
Updated May 3 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-20.50%

Although this company's net profit margin is negative, it is above the industry average and implies that Biomarin Pharmaceutical Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.00%Sector:HealthcareIndustry:Pharmaceuticals - Generic & Specialty
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2015Q3/2015Q2/2015Q1/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201512/31/2015Sep 30, 201509/30/2015Jun 30, 201506/30/2015Mar 31, 201503/31/2015
Revenue228209251203
Total other revenue--------
Total revenue228209251203
Gross profit185172211170
Total cost of revenue43374033
Total operating expense127291315269
Selling / general / administrative11493100100
Research & development176159158142
Depreciation / amortization8111
Interest expense (income), net operating--------
Unusual expense (income)-1710--0
Other operating expenses, total-441140
Operating income101-82-64-66
Interest income (expense), net non-operating-9-9-10-9
Gain (loss) on sale of assets--------
Other--------
Income before tax93-90-83-75
Income after tax69-91-82-68
Income tax, total240-1-7
Net income69-91-82-68
Total adjustments to net income--------
Net income before extra. items69-91-82-68
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items69-91-82-68
Inc. avail. to common incl. extra. items69-91-82-68
Diluted net income69-91-82-68
Dilution adjustment--------
Diluted weighted average shares161161160158
Diluted EPS excluding extraordinary itemsvalue per share0.43-0.57-0.51-0.43
Dividends per sharevalue per share--0.000.000.00
Diluted normalized EPSvalue per share-0.26-0.57-0.51-0.43